DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

**REGISTERED COMPANY NUMBER: 04133242 (England and Wales) REGISTERED CHARITY NUMBER: 1085527** 

Report of the Trustees and 

Unaudited Financial Statements for the Year Ended 31 December 2023 

for 

Anaphylaxis UK 

Chamberlains Chartered Accountants Elm House, Tanshire Park Shackleford Road, Elstead Godalming Surrey GU8 6LB 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 Anaphylaxis UK 

Contents of the Financial Statements for the Year Ended 31 December 2023 

|||Page||
|---|---|---|---|
|Report of the Trustees|1|to|8|
|Independent Examiner's Report||9||
|Statement of Financial Activities||10||
|Balance Sheet|11|to|12|
|Cash Flow Statement||13||
|Notes to the Cash Flow Statement||14||
|Notes to the Financial Statements|15|to|23|
|Detailed Statement of Financial Activities|24|to|25|





DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

## Report of the Trustees 

for the Year Ended 31 December 2023 

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2023. The trustees have adopted the provisions  of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS  102) (effective 1 January 2019). 

The Trustees, who are also the Directors of the Charity for the purposes of the Companies Act, are pleased to present their report, together with the annual financial statements for the year ended 31 December 2023. 

## **2023 - A Year of Remarkable Achievements and Unwavering Performance** 

## **Collaborating with Healthcare and Allergy Services** 

- We had the privilege of attending the prestigious BSACI conference in October 2023, where we presented a talk on alpha-gal allergy, shedding light on this critical emerging issue. 

- Developed a comprehensive new information booklet on Alpha-gal allergy, featuring compelling case studies and a comprehensive factsheet, empowering individuals with essential knowledge. 

- Created four visually captivating posters on best practices in prescribing AAIs, based on the 'Public Assessment  Report of the Commission on Human Medicines' Adrenaline Auto-injector Expert Working Group: Recommendations to support the effective and safe use of adrenaline auto-injectors. 

- Collaborated with Viatris on their inspiring Ready2React campaign, fostering a deeper understanding of the profound impact of living with allergies. 

- Served as an active member of the BRIT Registry (British Registry for Immunotherapy) steering group, contributing our expertise to support improved outcomes for patients undergoing immunotherapy. 

- Actively participated in CYANS (The Children and Young People's Allergy Network Scotland) ensuring the voices of children and young people are heard and their needs are addressed. 

- Developed a suite of podcasts, featuring our Chief Executive, Simon Williams, engaging in thought-provoking discussions with both healthcare professionals and members of the public affected by allergies. 

- Dr Helen Evans-Howells (trustee) was appointed as the esteemed chair of our clinical and scientific panel, working tirelessly with clinical colleagues to gain further engagement in the vital work of Anaphylaxis UK. 

- We published a monthly healthcare professionals' newsletter, keeping healthcare professionals informed about the latest developments in allergy and resources for their patients. This newsletter boasted an impressive opening rate of above 70%, reflecting its invaluable content. 

## **Health-related Research** 

- We collaborated with Southampton University (Professor Graham Roberts) on the groundbreaking 'Preventing food allergy in infants with early introduction of complementary feeding study.' 

- Partnered with The University of Birmingham on the FAIR Study (Food Allergy Inequality Research), 'Addressing inequalities in the management of food allergy in South Asian adults,' a critical endeavour to promote inclusivity and equity. 

- Actively promoted research initiatives at Aston University and supported PhD Students, fostering the advancement of scientific knowledge. 

Page 1 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

## Report of the Trustees 

for the Year Ended 31 December 2023 

## **Patient Information** 

- Achieved the prestigious re-accreditation for our patient information factsheets from the Patient Information Forum (PIF) Tick quality mark in November 2023, a testament to our unwavering commitment to providing accurate and reliable information. 

- Continued the extensive review and redevelopment of our entire library of factsheets, aligning them with our new updated website and brand guidelines, ensuring a cohesive and visually appealing experience for our audience. 

- Recruited 50 new lay reviewers to lend their invaluable perspectives and contribute to the review process of our factsheets, ensuring a comprehensive and user-friendly approach. 

- Collaborated with the MHRA on their AAI Safety Campaign, raising public awareness about the safe and effective  use of AAIs. 

- Responded to over 500 calls and over 1,200 emails on our dedicated helpline, providing personalized support and guidance to individuals in need. 

- Updated our method of logging helpline enquiries, transitioning from a Microsoft database to the Feedback module  on CRM, enhancing our ability to analyse calls and improve the support we offer. 

- Our popular Bee and Wasp Campaign returned triumphantly, running from May to September. We worked hand-in-hand with beekeeping societies across all four nations, developing a range of invaluable information resources to support the venom-allergic community. This included a captivating podcast with Dr Andrew Whyte, which garnered an impressive 5,500 views, a testament to its resonance and relevance. 

## **AllergyWise Training Program** 

- Relaunched our AllergyWise training courses on the new LearnDash platform, boasting a fresh look and updated content, ensuring our offerings remain cutting-edge and engaging. 

- Introduced new courses tailored for Out of School Settings and Workplaces, expanding our reach and impact. 

- Created new information resources to complement our course content, including risk assessments and practical scenarios, providing a comprehensive learning experience. 

- Celebrated a remarkable 135% improvement in AllergyWise School course sales, soaring from £50,788 to an impressive £119,151, reflecting the increasing demand for our high-quality educational offerings. 

- Achieved a 12% improvement in AllergyWise sales for Healthcare Professionals, Care Workers, Out of School Settings, and Workplace courses, rising from £17,170 to £19,298, a testament to the trust and confidence placed in our programs. 

## **Communications** 

## **Social media** 

- Our Facebook following grew to 20,000 with an impressive reach of 1.4 million, reflecting the resonance of our message and the strength of our online community. 

- Our Instagram following witnessed remarkable growth, reaching 7,900 and a reach of 157,000, showcasing the visual appeal of our content and the engagement of our audience. 

- Our LinkedIn presence flourished, with our followers growing to 1,800, fostering valuable professional connections and thought leadership. 

Page 2 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

## Report of the Trustees 

for the Year Ended 31 December 2023 

## **Newsletters** 

AllergyOutlook is our popular monthly newsletter featuring articles and news written to support people with allergies. The newsletter shines a spotlight on the tireless efforts of our charity, keeping subscribers informed about the latest initiatives, groundbreaking services, and the tangible impact we are making in the lives of individuals and families. In the past year alone, our subscriber base has flourished, expanding from 4,600 to 13,000, an astonishing achievement in the period.. 

## **Fundraising Highlights** 

- Our remarkable London Marathon 2023 runners exceeded their combined fundraising target by an astonishing 35%. We were fortunate to have an additional three ballot runners join our strong team of five, and collectively, they raised an impressive £15,322, a true testament to their dedication and the generosity of our supporters and all those involved with them. 

- A new and innovative fundraising challenge, #Challenge14, was created for Anaphylaxis Awareness Week 2023. This campaign invited supporters to fundraise in unique ways, incorporating the number 14 (e.g., repetitions, distance, donation ask value) within their challenge to raise awareness of the 14 major food allergens. We were humbled by the participation of 24 individuals - including beneficiaries, staff, trustees, schools, corporates, and suppliers - who collectively raised an incredible £6,245 (excluding Gift Aid), demonstrating the power of community and collective action. 

- For the first time, Anaphylaxis UK participated in Big Give's Christmas Challenge 2023, the UK's largest match-funded campaign. Our "A brighter future for people with serious allergies" campaign aimed to raise £10,000 from supporter pledges, match funding, and public donations. Within the week-long campaign, we not only achieved our target but exceeded it, raising a remarkable total of £10,284, a testament to the generosity and commitment of our supporters. 

## **FUNDRAISER FOCUS: #Challenge14 Participants** 

The participants of the inaugural #Challenge14 fundraising event truly embodied the spirit of determination and compassion, each undertaking a unique challenge to raise awareness of the 14 major food allergens. Among the  standout fundraisers were: 

- Lucy, a devoted mother, who raised an incredible £435 on a 14-mile walk in support of her young daughter's journey with allergies. 

- George, an 11-year-old with unwavering dedication, raised £310 by washing 14 cars in 7 days, demonstrating that age is no barrier to making a difference. 

- Our corporate sponsor, Nestle Health Science, contributed £664 to the fundraising pot through a lively quiz night and sweepstake, showcasing their commitment to our cause. 

- Saoirse, a young student, presented a school assembly to her classmates and walked an impressive 14km over 7 days, raising £98 and fostering awareness among her peers. 

## **FUNDRAISER FOCUS: 10 Years of Celebrating Will** 

For the past decade, friends and family of Will, who tragically passed away in 2013, have organised an annual charity golf day to raise funds for Anaphylaxis UK. To mark this significant anniversary, the 2023 event was bigger and better than ever, with 34 players and 60 evening guests, raising over £3,000. Over the last 10 years, an extraordinary £15,000 has been generously raised by Will's loved ones, honouring his memory and supporting our mission through their  greatly appreciated efforts. 

Page 3 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

for the Year Ended 31 December 2023 

## Report of the Trustees 

## **FUNDRAISER FOCUS: Charity Football Day** 

In a poignant and heartwarming tribute, friends and family came together in April 2023 to celebrate the memory of James, who tragically passed away from anaphylaxis in February 2018 at the age of 15. On what would have been his 21st birthday, they organised a charity football day, raffle, and auction for Anaphylaxis UK. The event was a resounding success, raising a staggering £5,857 on the day to celebrate James. 

## **Impactful Contributions** 

The generosity of our supporters has been truly awe-inspiring. Driven by an unwavering dedication to our cause, major donors contributed a remarkable £7,000, providing invaluable support that propelled our ongoing efforts forward. Additionally, we are deeply humbled by the £19,828 raised through heartfelt in memoriam donations, profound tributes that honour the memories of loved ones and underscore the profound impact of our work. 

Public donations, totalling an extraordinary £48,305, have been instrumental in fuelling our mission, enabling us to provide vital support services, education and advocacy for individuals and families affected by allergies. These contributions represent more than just financial assistance; they are a testament to the trust and belief our community has placed in us. 

## **Driving Change through Grants** 

Grants totalling £13,600 have been catalysts for our initiatives, empowering us to keep the allergy community safe and supported. Funding from esteemed Trusts such as The Brian Shaw Memorial Trust, The Ardwick Trust, and The Lady Hind Trust has enabled our information and services team to deliver essential support services to the public, ensuring that no one faces the challenges of allergies alone or without guidance. 

Moreover, grants from the CRH Charitable Trust, The Anton Jurgens Charitable Trust, and the Hospital Saturday  Fund have paved the way for the development of our pioneering AllergyWise training for Early Years settings. This groundbreaking initiative equips caregivers and educators with the knowledge and tools necessary to create safer environments for children with allergies, fostering inclusivity and protection from a young age. 

## **Anaphylaxis UK Business Symposium** 

This flagship event, held at the renowned Francis Crick Institute in London in December 2023, was a resounding success. We raised an impressive £26,500 from sponsors of the business symposium, with generous contributions from esteemed partners including RSSL, SGS, ServeLegal, Romer Labs, Neogen, Thermo Fisher Scientific, DBV Technologies, and Christeyns Food Hygiene. This significant support has bolstered our initiatives, enabling us to advance our mission of fostering inclusion and awareness within society. 

Additionally, our corporate members' unwavering commitment generated an incredible £75,885 through their memberships. Their partnership has been instrumental in driving positive change and expanding our outreach efforts, amplifying our impact and ensuring our message resonates far and wide. 

Through the collective efforts of our dedicated supporters, tireless volunteers, and passionate team members, we have achieved remarkable milestones in 2023. These achievements are not merely statistics or figures; they represent lives transformed, hope rekindled, and a future where individuals with allergies can live with confidence, empowerment, and  a profound sense of community. 

As we look ahead, we are filled with renewed determination and optimism, fuelled by the successes of the past year and the unwavering commitment. Together, we will continue to forge ahead, advocating for change, raising awareness, and ensuring that no one faces the challenges of allergies alone. 

Page 4 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Report of the Trustees for the Year Ended 31 December 2023 

## **Investment performance achieved against investment objectives** 

The investment objectives of the Charity are to maximise the value of reserves, while avoiding undue risk. The  Charity's policy on investment includes a requirement to limit investments to 60% of liquid assets and only to invest in Funds regulated by the Financial Conduct Authority. The Charity's investments in an Income and Growth portfolio with Hargreaves Lansdown showed a gain of £9,471 on the value report at the end of December 2022 (£154,824). The value at the end of December 2023 was £164,295. 

## **Financial review: Reserves policy** 

To achieve a sound balance between prudence and ensuring funds are expended in achieving the objectives of the Charity, the Trustees have established a policy whereby the unrestricted reserves held by the Charity should equate to at least six months operating costs. At the year end this equated to £245,182. Free reserves (excluding 6 months operating costs) at 31 December 2023 stood at £386,685. 

## **Restricted reserves** 

There were no restricted reseves at 31 December 2023. 

## **Risk review** 

The Trustees have conducted a review of the major risks to which the Charity is exposed and systems have been established to manage those risks. A risk management register is maintained and risks highlighted are reviewed  regularly to ensure they do not pose a threat to the Charity going forward. Key risks for the Charity include an uncertain  economic outlook and its impact on fundraising by individuals and financial support from businesses. 

## **Financial overview** 

The Charity ended the year in a sound financial position with sufficient free reserves to meet its reserves policy. Net outgoing resources for the year amounted to £579,487. Unrestricted funds were £631,867 and restricted funds were zero. 

## **Financial policies** 

All payments up to £10,000 made by the Charity have to be signed by two authorised signatories and by a Trustee in addition for payments over that amount. The day-to-day management of the financial affairs of the Charity is  delegated to the Head of Finance and Operations who submits Management Accounts and a written report monthly to the CEO  and Board of Trustees. A financial report supported by Management Accounts is delivered at each meeting of Trustees. 

## **Principal funding sources** 

The principal funding sources for the charity are community fundraising initiatives such as the London Marathon, sales from our AllergyWise training programme and from Business Membership. The charity also benefits from grants and sponsorship of project work such as awareness campaigns. 

## **Use of funds** 

Funds received by the charity have contributed significantly to the expansion of services offered by the Information Team and in our ability to enhance our awareness campaigns to reach more people with allergies. 

Page 5 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

## Report of the Trustees 

for the Year Ended 31 December 2023 

## **Plans for the future** 

The Board have agreed a Strategic Framework for 2023-2028. The general impact the Anaphylaxis UK charity aims to achieve by the end of 2028 is: 

We want everyone with a serious allergy to enjoy the same quality of life as someone without an allergy. Over the next five years, all of our work will focus on making this ambition a reality. 

Our main priority areas and the impact we aim to achieve within each area are set out in the Business Plan since they were approved by the Board in March 2023. The main areas for future work are: 

## **- Empowering Lives, Conquering Fears in the Years Ahead** 

For too long, the anxiety of living with an allergy has robbed individuals of the freedom to fully embrace life's  cherished moments - from joyous birthday celebrations to simple acts of socialising and exploring the world around them. The ever-present fear of a potential reaction has cast a shadow over the everyday, creating an unacceptable barrier to living life to the fullest. But today, we stand united in our resolve to shatter those barriers and empower our community to reclaim their lives without fear. 

Following the success of a groundbreaking Knowledge Transfer (KTP) grant, we are thrilled to announce an unprecedented partnership with the esteemed University of Surrey. Together, we will embark on an ambitious journey, collaborating with renowned clinical psychologists to develop a transformative support system. This pioneering  program will equip individuals with the tools and strategies to conquer their anxieties, empowering them with the skills to navigate life's adventures with confidence and resilience. 

This visionary initiative marks a milestone in the evolution of our charity, as we expand our horizons to offer life-changing services tailored to the unique needs of our beneficiaries. No longer will fear dictate their choices; instead, they will be equipped with the knowledge and self-assurance to embrace every opportunity, every moment, and every dream. 

## **- Safer Schools, Brighter Futures** 

Recognising the pivotal role of educational institutions in fostering an inclusive and supportive environment, we will expand our acclaimed AllergyWise portfolio, with a particular emphasis on our Safer Schools Programme. Through  this initiative, we will actively encourage more schools to undertake comprehensive training and adopt robust policies and procedures, ensuring that every student with allergies can learn, grow, and thrive in a nurturing and secure environment. 

## **- Forging Powerful Partnerships** 

In our unwavering pursuit of promoting awareness and understanding, we will enhance our relationships with leading businesses, forging powerful partnerships that amplify our collective impact. Together, we will embark on groundbreaking awareness-raising programs, fostering a culture of inclusion and empathy that transcends boundaries. 

## **- Empowering Businesses, Enriching Lives** 

Recognising the vital role that small and medium-sized enterprises play in shaping our communities, we will develop an innovative online portal - a comprehensive resource tailored to their unique needs. This dynamic platform will serve as  a trusted guide, providing factually accurate support, resources, and insights to help businesses navigate the complexities of allergies with ease. From developing allergy-aware products and services to fostering inclusive practices, we will empower these enterprises to become catalysts for positive change, creating a world where accessibility and understanding are woven into the very fabric of society. 

Page 6 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Report of the Trustees for the Year Ended 31 December 2023 

## **- Accessible Information, Trusted Source** 

Our commitment to providing accurate and trusted information will reach new heights as we embrace diverse mediums to cater to the evolving needs of our beneficiaries. Through captivating infographics, engaging animations, and informative videos, we will ensure that our factsheets and resources are not only informative but also accessible and engaging. By meeting our community where they are, we will solidify our position as the premier trusted source of information, empowering individuals to make informed decisions and navigate their journey with confidence. 

Together, we stand at the precipice of a transformative era, where the weight of anxiety is lifted, and the freedom to embrace life's every opportunity is within reach. 

## **Statement of Trustees' responsibilities** 

The trustees (who are also directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to: 

- select suitable accounting policies and then apply them consistently; 

- observe the methods and principles in the Charities SORP; 

- make judgements and estimates that are reasonable and prudent; 

- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; 

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation. 

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

## In so far as the trustees are aware: 

- there is no relevant audit information of which the charitable company's auditor is unaware; and 

- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information. 

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on  the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. 

## **Independent Examiners** 

Chamberlains were appointed independent at the Annual General Meeting of the Charity held on 10th June 2024. 

## **STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document** 

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006. 

## **REFERENCE AND ADMINISTRATIVE DETAILS** 

## **Registered Company number** 

04133242 (England and Wales) 

Page 7 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Report of the Trustees for the Year Ended 31 December 2023 

## **Registered Charity number** 

1085527 

## **Registered office** 

1 Alexandra Road Farnborough GU14 6BU 

## **Trustees** 

Dr A M Walker-Fraser Chair Mr P M Littleton Vice Chair Mr C Meads (resigned 8.6.23) Mrs T Randhawa Mrs L C Wilkinson Mrs S C Hall (resigned 10.4.24) Dr H E Evans-Howells Mr R J Wright KC Mr B Gaventa (resigned 10.3.23) Ms C C A Fearnley (appointed 17.7.23) 

## **Company Secretary** 

Mrs L A Ingram 

## **Independent Examiner** 

Paul J Chamberlain FCA DChA Chamberlains Chartered Accountants Elm House, Tanshire Park Shackleford Road, Elstead Godalming Surrey GU8 6LB 

12 June 2024 Approved by order of the board of trustees on ............................................. and signed on its behalf by: 

[A ........................................................................ 1C4B1FCD180E469...ea by: Dr A M Walker-Fraser - Trustee 

Page 8 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Independent Examiner's Report to the Trustees of Anaphylaxis UK 

## **Independent examiner's report to the trustees of Anaphylaxis UK ('the Company')** 

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2023. 

## **Responsibilities and basis of report** 

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible  for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act'). 

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act. 

## **Independent examiner's statement** 

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies. 

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe: 

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or 

2. the accounts do not accord with those records; or 

3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an  independent examination; or 

4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their  accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)). 

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. 

Paul J Chamberlain FCA DChA The Institute of Chartered Accountants in England and Wales 

Chamberlains Chartered Accountants Elm House, Tanshire Park Shackleford Road, Elstead Godalming Surrey GU8 6LB 12 June 2024 Date: ............................................. 

Page 9 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

## Statement of Financial Activities for the Year Ended 31 December 2023 

|Unrestricted<br>fund<br>Notes<br>£<br>**INCOME FROM**<br>Donations and legacies<br>2<br>551,512<br>**Charitable activities**<br>5<br>Sale of educational products<br>-<br>Product recall income<br>-<br>Other trading activities<br>3<br>31,202<br>Investment income<br>4<br>3,383<br>**Total**<br>586,097<br>**EXPENDITURE ON**<br>Raising funds<br>6<br>79,256<br>**Charitable activities**<br>7<br>Charitable activities<br>496,285<br>Other<br>3,946<br>**Total**<br>579,487<br>Net gains/(losses) on investments<br>9,471<br>**NET INCOME**<br>16,081<br>**RECONCILIATION OF FUNDS**<br>Total funds brought forward<br>613,648<br>**TOTAL FUNDS CARRIED FORWARD**<br>629,729|Restricted<br>funds<br>£<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|31.12.23<br>31.12.22<br>Total<br>Total<br>funds<br>funds<br>£<br>£<br>551,512<br>354,712<br>-<br>68,116<br>-<br>42,902<br>31,202<br>73,134<br>3,383<br>2,030<br>586,097<br>540,894<br>79,256<br>76,821<br>496,285<br>421,369<br>3,946<br>31,347<br>579,487<br>529,537<br>9,471<br>(8,078)<br>16,081<br>3,279<br>613,648<br>610,369<br>629,729<br>613,648|
|---|---|---|



The notes form part of these financial statements 

Page 10 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

## Balance Sheet 

## 31 December 2023 

|Unrestricted<br>fund<br>Notes<br>£<br>**FIXED ASSETS**<br>Intangible assets<br>13<br>37,963<br>Tangible assets<br>14<br>10,933<br>Investments<br>15<br>164,296<br>213,192<br>**CURRENT ASSETS**<br>Stocks<br>16<br>311<br>Debtors<br>17<br>150,045<br>Cash in hand<br>322,519<br>472,875<br>**CREDITORS**<br>Amounts falling due within one year<br>18<br>(56,338)<br>**NET CURRENT ASSETS**<br>416,537<br>**TOTAL ASSETS LESS CURRENT**<br>**LIABILITIES**<br>629,729<br>**NET ASSETS**<br>629,729<br>**FUNDS**<br>19<br>Unrestricted funds<br>**TOTAL FUNDS**|Restricted<br>funds<br>£<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-<br>-|31.12.23<br>Total<br>funds<br>£<br>37,963<br>10,933<br>164,296<br>213,192<br>311<br>150,045<br>322,519<br>472,875<br>(56,338)<br>416,537<br>629,729<br>629,729<br>629,729<br>629,729|31.12.22<br>Total<br>funds<br>£<br>43,183<br>15,035<br>154,824<br>213,042<br>828<br>70,689<br>373,041<br>444,558<br>(43,952)<br>400,606<br>613,648<br>613,648<br>613,648<br>613,648|
|---|---|---|---|



The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023. 

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006. 

The trustees acknowledge their responsibilities for 

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and 

- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company  as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company. 

The notes form part of these financial statements 

continued... 

Page 11 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

## Balance Sheet - continued 31 December 2023 

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime. 

The financial statements were approved by the Board of Trustees and authorised for issue on 12 June 2024 ............................................. and were signed on its behalf by: 

............................................. [A1C4B1FCD180E469...ea by: Dr A M Walker-Fraser - Trustee 

The notes form part of these financial statements 

Page 12 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

## Anaphylaxis UK 

Cash Flow Statement for the Year Ended 31 December 2023 

|Notes<br>**Cash flows from operating activities**<br>Cash generated from operations<br>1<br>Net cash (used in)/provided by operating activities<br>**Cash flows from investing activities**<br>Purchase of intangible fixed assets<br>Purchase of tangible fixed assets<br>Purchase of fixed asset investments<br>Sale of intangible fixed assets<br>Sale of tangible fixed assets<br>Interest received<br>Net cash used in investing activities<br>**Change in cash and cash equivalents in**<br>**the reporting period**<br>**Cash and cash equivalents at the**<br>**beginning of the reporting period**<br>**Cash and cash equivalents at the end of**<br>**the reporting period**|31.12.23<br>£<br>(37,824)<br>(37,824)<br>(12,632)<br>(3,448)<br>(1)<br>2,950<br>(2,950)<br>3,383<br>(12,698)<br>(50,522)<br>373,041<br>322,519|31.12.22<br>£<br>19,714<br>19,714<br>(45,670)<br>(8,909)<br>-<br>-<br>5,265<br>2,030<br>(47,284)<br>(27,570)<br>400,611<br>373,041|
|---|---|---|



The notes form part of these financial statements 

Page 13 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Notes to the Cash Flow Statement for the Year Ended 31 December 2023 

## **1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES** 

||31.12.23|31.12.22|
|---|---|---|
||£|£|
|**Net income for the reporting period (as per the Statement of Financial**|||
|**Activities)**|16,081|3,279|
|**Adjustments for:**|||
|Depreciation charges|21,456|15,710|
|(Gain)/losses on investments|(9,471)|8,078|
|Loss on disposal of fixed assets|3,946|-|
|Interest received|(3,383)|(2,030)|
|Decrease in stocks|517|2,379|
|Increase in debtors|(79,357)|(13,551)|
|Increase in creditors|12,387|5,849|
|**Net cash (used in)/provided by operations**|(37,824)|19,714|



## **2. ANALYSIS OF CHANGES IN NET FUNDS** 

|**Net cash**|At 1.1.23<br>£|Cash flow<br>£|At 31.12.23<br>£|At 31.12.23<br>£|
|---|---|---|---|---|
|Cash at bank and in hand|373,041|(50,522)||322,519|
||373,041|(50,522)||322,519|
|**Total**|373,041|(50,522)||322,519|



The notes form part of these financial statements 

Page 14 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 Anaphylaxis UK 

Notes to the Financial Statements 

for the Year Ended 31 December 2023 

## **1. ACCOUNTING POLICIES** 

## **Basis of preparing the financial statements** 

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the  revaluation of certain assets. 

## **Preparation of consolidated financial statements** 

The financial statements contain information about Anaphylaxis UK as an individual company and do not contain consolidated financial information as the parent of a group. The charity is exempt under Section  399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements. 

Anaphylaxis UK has one subsidiary, Anaphylaxis UK Trading Ltd. The registered office of the subsidiary is 1 Alexandra Road, Farnborough, GU14 6BU. Anaphylaxis UK owns 100% of the £1 ordinary share capital of  the subsidiary. 

The subsidiary company carries out trading activities related to the objectives of Anaphylaxis UK. All the taxable profits of the subsidiary are paid by gift to Anaphylaxis UK and are used in the furtherance of the charity's objectives. Consequently, the total reserves of the subsidiary are its £1 ordinary share capital. 

Total income and expenditure of the subsidiary in the year to 31 December 2023 were £264,800, including ££200,940 paid by gift to Anaphylaxis UK. 

## **Income** 

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. 

## **Expenditure** 

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. 

## **Tangible fixed assets** 

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. 

Plant and machinery 

- 25% on cost 

## **Stocks** 

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and  slow moving items. 

## **Taxation** 

The charity is exempt from corporation tax on its charitable activities. 

## **Fund accounting** 

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. 

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. 

continued... 

Page 15 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Notes to the Financial Statements - continued for the Year Ended 31 December 2023 

## **1. ACCOUNTING POLICIES - continued** 

## **Fund accounting** 

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements. 

## **Hire purchase and leasing commitments** 

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease. 

## **Investments** 

Fixed asset investments are treated as a single asset, revalued each year to current market value. 

## **2. DONATIONS AND LEGACIES** 

|Donations - members<br>Memoriam donations<br>Gift aid<br>Community fundraising & events<br>Charitable trusts and major donors<br>Corporate donations<br>Legacies<br>Individual membership<br>Professional membership<br>Corporate membership<br>Other including Google Adwords<br>Income from subsidiary|31.12.23<br>£<br>27,638<br>19,828<br>27,636<br>46,233<br>20,600<br>7,135<br>501<br>43,876<br>2,443<br>-<br>96,733<br>258,889<br>551,512|31.12.22<br>£<br>29,595<br>30,151<br>37,906<br>23,386<br>38,600<br>8,825<br>13,986<br>47,433<br>3,096<br>57,955<br>63,779<br>-<br>354,712|
|---|---|---|



Since 1 January 2023 a number of activities previously undertaken by Anaphylaxis UK have been carried out  by its subsidiary, Anaphylaxis UK Trading Ltd. These include corporate membership, Allergywise training,  product recall work, events, special projects and some other activities. All of Anaphylaxis UK Trading Ltd's surplus for the year is gifted to Anaphylaxis UK and is included in Donations and Legacies. 

## **3. OTHER TRADING ACTIVITIES** 

|**OTHER TRADING ACTIVITIES**||
|---|---|
|Shop income|31.12.23<br>31.12.22<br>£<br>£<br>-<br>909|
|Event income|15,322<br>16,441|
|Special project income|12,380<br>43,700|
|Other sundry income|-<br>8,784|
|Corporate sponsorship|3,500<br>3,300|
||31,202<br>73,134|



continued... 

Page 16 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Notes to the Financial Statements - continued for the Year Ended 31 December 2023 

## **4. INVESTMENT INCOME** 

|**INVESTMENT INCOME**|||
|---|---|---|
||31.12.23|31.12.22|
||£|£|
|Dividends and interest rec'd|3,383|2,030|



## **5. INCOME FROM CHARITABLE ACTIVITIES** 

The split of income from charitable activities is shown in the Statement of Financial Activities. 

## **6. RAISING FUNDS** 

## **Raising donations and legacies** 

|Staff costs<br>Other fundraising costs<br>Support costs<br>**7.**<br>**CHARITABLE ACTIVITIES COSTS**<br>Charitable activities<br>**8.**<br>**SUPPORT COSTS**<br>Raising donations and legacies<br>Charitable activities<br>**9.**<br>**NET INCOME/(EXPENDITURE)**<br>Net income/(expenditure) is stated after charging/(crediting):<br>Audit fee<br>Auditor's remuneration for other work<br>Depreciation - owned assets<br>Hire of plant and machinery<br>Other operating leases<br>Deficit on disposal of fixed assets<br>Computer software amortisation|31.12.23<br>£<br>26,269<br>10,650<br>42,337<br>79,256<br>Support<br>Direct<br>costs (see<br>Costs<br>note 8)<br>£<br>£<br>305,376<br>190,909<br>General<br>Governance<br>costs<br>costs<br>£<br>£<br>42,337<br>-<br>157,586<br>33,323<br>199,923<br>33,323<br>31.12.23<br>£<br>-<br>-<br>6,554<br>7,705<br>45,246<br>3,946<br>14,902|31.12.22<br>£<br>24,224<br>9,457<br>43,140<br>76,821<br>Totals<br>£<br>496,285<br>Totals<br>£<br>42,337<br>190,909<br>233,246<br>31.12.22<br>£<br>5,150<br>750<br>5,880<br>8,775<br>34,723<br>-<br>9,830|
|---|---|---|



continued... 

Page 17 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Notes to the Financial Statements - continued for the Year Ended 31 December 2023 

## **10. TRUSTEES' REMUNERATION AND BENEFITS** 

There were no trustees' remuneration or other benefits for the year ended 31 December 2023 nor for the year ended 31 December 2022. 

## **Trustees' expenses** 

There were no trustees' expenses paid for the year ended 31 December 2023 nor for the year ended 31 December 2022. 

## **11. STAFF COSTS** 

|Wages and salaries<br>The average monthly number of employees during the year was as follows:<br>Fundraising<br>Charitable activities|31.12.23<br>£<br>305,647<br>305,647<br>31.12.23<br>1<br>7<br>8|31.12.22<br>£<br>286,898<br>286,898<br>31.12.22<br>1<br>7<br>8|
|---|---|---|



The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was: 

||£60,001 - £70,000||31.12.23<br>-||31.12.22<br>1|
|---|---|---|---|---|---|
||£70,001 - £80,000||1||-|
||||1||1|
|**12.**|**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**|||||
||**INCOME FROM**|Unrestricted<br>fund<br>£|Restricted<br>funds<br>£||Total<br>funds<br>£|
||Donations and legacies|354,712||-|354,712|
||**Charitable activities**|||||
||Sale of educational products|68,116||-|68,116|
||Product recall income|42,902||-|42,902|
||Other trading activities|73,134||-|73,134|
||Investment income|2,030||-|2,030|
||**Total**|540,894||-|540,894|
||**EXPENDITURE ON**|||||
||Raising funds|76,821||-|76,821|
||**Charitable activities**|||||
||Charitable activities|418,226|3,143||421,369|



continued... 

Page 18 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Notes to the Financial Statements - continued for the Year Ended 31 December 2023 

|**12.**|**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued**|**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued**|**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued**|**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued**||
|---|---|---|---|---|---|
|||Unrestricted|Restricted||Total|
|||fund|funds||funds|
|||£|£||£|
||Other|31,347||-|31,347|
||**Total**|526,394|3,143||529,537|
||Net gains/(losses) on investments|(8,078)||-|(8,078)|
||**NET INCOME/(EXPENDITURE)**|6,422|(3,143)||3,279|
||**RECONCILIATION OF FUNDS**|||||
||Total funds brought forward|607,226|3,143||610,369|
||**TOTAL FUNDS CARRIED FORWARD**|613,648||-|613,648|
|**13.**|**INTANGIBLE FIXED ASSETS**|||||
||**COST**||||Computer<br>software<br>£|
||At 1 January 2023||||58,911|
||Additions||||12,632|
||Disposals||||(13,241)|
||At 31 December 2023||||58,302|
||**AMORTISATION**|||||
||At 1 January 2023||||15,728|
||Charge for year||||14,902|
||Eliminated on disposal||||(10,291)|
||At 31 December 2023||||20,339|
||**NET BOOK VALUE**|||||
||At 31 December 2023||||37,963|
||At 31 December 2022||||43,183|



continued... 

Page 19 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Notes to the Financial Statements - continued for the Year Ended 31 December 2023 

## **14. TANGIBLE FIXED ASSETS** 

|**TANGIBLE FIXED ASSETS**||
|---|---|
||Plant and|
||machinery|
||£|
|**COST**||
|At 1 January 2023|37,850|
|Additions|3,448|
|Disposals|(15,409)|
|At 31 December 2023|25,889|
|**DEPRECIATION**||
|At 1 January 2023|22,815|
|Charge for year|6,554|
|Eliminated on disposal|(14,413)|
|At 31 December 2023|14,956|
|**NET BOOK VALUE**||
|At 31 December 2023|10,933|
|At 31 December 2022|15,035|



## **15. FIXED ASSET INVESTMENTS** 

|Shares in<br>group<br>Listed<br>undertakings<br>investments<br>£<br>£<br>**MARKET VALUE**<br>At 1 January 2023<br>-<br>154,824<br>Additions<br>1<br>-<br>Revaluations<br>-<br>9,471<br>At 31 December 2023<br>1<br>164,295<br>**NET BOOK VALUE**<br>At 31 December 2023<br>1<br>164,295<br>At 31 December 2022<br>-<br>154,824|Totals<br>£<br>154,824<br>1<br>9,471<br>164,296<br>164,296<br>154,824|
|---|---|



There were no investment assets outside the UK. 

Anaphylaxis UK holds the entire £1 share capital of its trading subsidiary Anaphylaxis UK Trading Ltd. The subsidiary began trading on 1 January 2023 and its income for the year to 31 December 2023 was £289,629.  The subsidiary gifts its taxable profit to Anaphylaxis UK and consequently it had no reserves at 31 December 2023 other than its share capital of £1. 

Listed fixed asset investments are revalued each year by the external fund managers. 

continued... 

Page 20 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Notes to the Financial Statements - continued for the Year Ended 31 December 2023 

|**16.**<br>**STOCKS**<br>Finished goods<br>**17.**<br>**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**<br>Trade debtors<br>Amounts owed by group undertakings<br>VAT<br>Prepayments and accrued income<br>Accrued income<br>**18.**<br>**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**<br>Trade creditors<br>Social security and other taxes<br>Accruals and deferred income<br>Accrued expenses<br>**19.**<br>**MOVEMENT IN FUNDS**<br>At 1.1.23<br>£<br>**Unrestricted funds**<br>General fund<br>613,648<br>**TOTAL FUNDS**<br>613,648<br>Net movement in funds, included in the above are as follows:<br>Incoming<br>Resources<br>resources<br>expended<br>£<br>£<br>**Unrestricted funds**<br>General fund<br>586,097<br>(579,487)<br>**TOTAL FUNDS**<br>586,097<br>(579,487)|31.12.23<br>31.12.22<br>£<br>£<br>311<br>828<br>31.12.23<br>31.12.22<br>£<br>£<br>3,784<br>23,449<br>85,643<br>-<br>5,105<br>2,190<br>45,801<br>36,903<br>9,712<br>8,147<br>150,045<br>70,689<br>31.12.23<br>31.12.22<br>£<br>£<br>39,960<br>29,564<br>6,625<br>5,078<br>1,948<br>2,469<br>7,805<br>6,841<br>56,338<br>43,952<br>Net<br>movement<br>At<br>in funds<br>31.12.23<br>£<br>£<br>16,081<br>629,729<br>16,081<br>629,729<br>Gains and<br>Movement<br>losses<br>in funds<br>£<br>£<br>9,471<br>16,081<br>9,471<br>16,081|
|---|---|



continued... 

Page 21 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Notes to the Financial Statements - continued for the Year Ended 31 December 2023 

## **19. MOVEMENT IN FUNDS - continued** 

**Comparatives for movement in funds** 

|At 1.1.22<br>£<br>**Unrestricted funds**<br>General fund<br>607,226<br>**Restricted funds**<br>Isle of Man Fund<br>3,143<br>**TOTAL FUNDS**<br>610,369<br>Comparative net movement in funds, included in the above are as follows:<br>Incoming<br>Resources<br>resources<br>expended<br>£<br>£<br>**Unrestricted funds**<br>General fund<br>540,894<br>(526,394)<br>**Restricted funds**<br>Isle of Man Fund<br>-<br>(3,143)<br>**TOTAL FUNDS**<br>540,894<br>(529,537)<br>A current year 12 months and prior year 12 months combined position is as follows:<br>At 1.1.22<br>£<br>**Unrestricted funds**<br>General fund<br>607,226<br>**Restricted funds**<br>Isle of Man Fund<br>3,143<br>**TOTAL FUNDS**<br>610,369|Net<br>movement<br>At<br>in funds<br>31.12.22<br>£<br>£<br>6,422<br>613,648<br>(3,143)<br>-<br>3,279<br>613,648<br>Gains and<br>Movement<br>losses<br>in funds<br>£<br>£<br>(8,078)<br>6,422<br>-<br>(3,143)<br>(8,078)<br>3,279<br> <br>Net<br>movement<br>At<br>in funds<br>31.12.23<br>£<br>£<br>22,503<br>629,729<br>(3,143)<br>-<br>19,360<br>629,729|
|---|---|



continued... 

Page 22 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Notes to the Financial Statements - continued 

for the Year Ended 31 December 2023 

## **19. MOVEMENT IN FUNDS - continued** 

A current year 12 months and prior year 12 months combined net movement in funds, included in the above  are as follows: 

|Incoming<br>Resources<br>resources<br>expended<br>£<br>£<br>**Unrestricted funds**<br>General fund<br>1,126,991<br>(1,105,881)<br>**Restricted funds**<br>Isle of Man Fund<br>-<br>(3,143)<br>**TOTAL FUNDS**<br>1,126,991<br>(1,109,024)|Gains and<br>Movement<br>losses<br>in funds<br>£<br>£<br>1,393<br>22,503<br>-<br>(3,143)<br>1,393<br>19,360|
|---|---|



## **20. RELATED PARTY DISCLOSURES** 

In October 2022 a subsidiary company, Anaphylaxis UK Trading Ltd, was formed. This subsidiary  commenced trading in 2023. In the year to 31 December 2023 the subsidiary had income of £289,629. In accordance with the agreement between the two entities, the whole of Anaphylaxis UK Trading Ltd's taxable profit of £200,940 was paid to Anaphylaxis UK. 

Page 23 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

Detailed Statement of Financial Activities for the Year Ended 31 December 2023 

|Detailed Statement of Financial Activities<br>for the Year Ended 31 December 2023|||
|---|---|---|
||31.12.23|31.12.22|
||£|£|
|**INCOME**|||
|**Donations and legacies**|||
|Donations - members|27,638|29,595|
|Memoriam donations|19,828|30,151|
|Gift aid|27,636|37,906|
|Community fundraising & events|46,233|23,386|
|Charitable trusts and major donors|20,600|38,600|
|Corporate donations|7,135|8,825|
|Legacies|501|13,986|
|Individual membership|43,876|47,433|
|Professional membership|2,443|3,096|
|Corporate membership|-|57,955|
|Other including Google Adwords|96,733|63,779|
|Income from subsidiary|258,889|-|
|**Other trading activities**|551,512|354,712|
|Shop income|-|909|
|Event income|15,322|16,441|
|Special project income|12,380|43,700|
|Other sundry income|-|8,784|
|Corporate sponsorship|3,500|3,300|
|**Investment income**|31,202|73,134|
|Dividends and interest rec'd|3,383|2,030|
|**Charitable activities**|||
|Sale of educational products|-|68,116|
|Product recall income|-|42,902|
||-|111,018|
|**Total incoming resources**|586,097|540,894|
|**EXPENDITURE**|||
|**Raising donations and legacies**|||
|Wages|26,269|24,224|
|Other fundraising costs|10,650|9,457|
||36,919|33,681|
|**Charitable activities**|||
|Wages|184,957|188,163|
|Shop and activity purchases|92,745|84,629|
|Carried forward|277,702|272,792|



This page does not form part of the statutory financial statements 

Page 24 



DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 

Anaphylaxis UK 

|Detailed Statement of Financial Activities|||
|---|---|---|
|for the Year Ended 31 December 2023|||
||31.12.23|31.12.22|
||£|£|
|**Charitable activities**|||
|Brought forward|277,702|272,792|
|Contractor costs|19,695|23,800|
|Conference and events|1,636|694|
|Special projects|6,343|5,607|
|**Other**|305,376|302,893|
|Loss on sale of tangible fixed assets|3,946|-|
|**Support costs**|||
|**General costs**|||
|Wages|67,598|49,397|
|Rent and rates|7,705|8,775|
|Computer and software costs|45,246|34,723|
|Telephone|5,983|5,412|
|Travel and subsistence|2,150|2,072|
|Recruitment and redundancy|421|757|
|Staff training|2,034|2,074|
|Office expenses|1,091|2,625|
|Stationery and printing|620|102|
|Postage and carriage|246|2,160|
|Professional fees|2,119|4,678|
|Website costs|1,524|3,189|
|Insurance|2,018|2,350|
|Irrecoverable VAT|22,745|15,447|
|Sundry|10,627|6,904|
|Bank charges|6,340|5,241|
|Plant and machinery|21,456|15,710|
|**Governance costs**|199,923|161,616|
|Wages|26,823|25,114|
|Auditors' remuneration|-|5,900|
|Sundries|-|333|
|Accountancy and legal fees|6,500|-|
||33,323|31,347|
|Total resources expended|579,487|529,537|
|**Net income**|6,610|11,357|
||||



This page does not form part of the statutory financial statements 

Page 25